Results 81 to 90 of about 430,076 (285)

Assessment of Myocardial Scar; Comparison between F-FDG PET, CMR and Tc-Sestamibi

open access: yesClinical Medicine Insights: Cardiology, 2009
Objective Patients with heart failure and ischaemic heart disease may obtain benefit from revascularisation if viable dysfunctional myocardium is present.
Andrew Crean   +4 more
doaj   +1 more source

Assessment of scarring time in myocardial infarction

open access: yesKazan medical journal, 1986
The aim of this work was to study the concentration of collagen metabolite peptide-bound hydroxyproline in the dynamic observation of patients with myocardial infarction. We observed 80 patients, including 50 patients (31 men and 19 women) with myocardial infarction aged 34-72 years.
A. E. Vtorov, S. A. Kalinina
openaire   +2 more sources

Transmural Myocardial Scar Assessed by Cardiac Computed Tomography:Predictor of Echocardiographic Versus Clinical Response to Cardiac Resynchronization Therapy?

open access: yes, 2019
OBJECTIVES: Before cardiac resynchronization therapy (CRT) implantation, cardiac computed tomography (CT) can provide assessment of cardiac venous anatomy and visualize left ventricular (LV) myocardial scar.
Daniel Benjamin Fyenbo   +15 more
core   +1 more source

Presentation_1_Modified GAN Augmentation Algorithms for the MRI-Classification of Myocardial Scar Tissue in Ischemic Cardiomyopathy.PPTX

open access: yes, 2021
Contrast-enhanced cardiac magnetic resonance imaging (MRI) is routinely used to determine myocardial scar burden and make therapeutic decisions for coronary revascularization.
Swati D. Sonkawade (11423695)   +6 more
core   +1 more source

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay   +5 more
wiley   +1 more source

Bridging the translational gap in clinical nanomedicine: From rational design to clinical reality

open access: yesBMEMat, EarlyView.
Nanotechnology offers a multi‐faceted approach to modern healthcare, encompassing high‐sensitivity diagnostic imaging, innovative vaccine delivery, and targeted therapeutics. This review explores how these nanomedicine applications address critical challenges in cancer recurrence and the treatment of neurologic and respiratory diseases to combat rising
Ahmed H. Ghonaim   +9 more
wiley   +1 more source

Prevalence of scarred and dysfunctional myocardium in patients with heart failure of ischaemic origin: A cardiovascular magnetic resonance study

open access: yesJournal of Cardiovascular Magnetic Resonance, 2011
Background Cardiovascular magnetic resonance (CMR) with late gadolinium enhancement (LGE) can provide unique data on the transmural extent of scar/viability.
Wong Kenneth   +11 more
doaj   +1 more source

In silico analysis of putative interactions identifies fibroblasts as hubs for cell–cell communication during early regeneration of the zebrafish heart

open access: yesDevelopmental Dynamics, EarlyView.
Abstract Background The zebrafish heart regenerates upon injury. During injury response, fibroblasts and endothelial cells accumulate at the site of damage, and cardiomyocyte cell cycle reentry allows cardiac muscle regrowth. It is relevant to understand how the different cell types communicate with each other to coordinate regeneration.
João A. S. Carvalho   +6 more
wiley   +1 more source

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler   +4 more
wiley   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy